Due to the COVID-19 pandemic, the ACP office is closed to the public as our staff work remotely. Click here to see how this impacts our programs and operations.

Valsartan recall update

September 19, 2018

Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA.

Health Canada is sharing the results of its review of potential long-term health effects involving valsartan drugs that were found to contain the impurity N-nitrosodimethylamine (NDMA). Health Canada scientists have assessed the available data to determine the potential increased risk of developing cancer, to help put the risk into context for Canadians.

For complete details, visit the Health Canada website.

← Previous ArticleNext Article →